is rybelsus a glp-1 Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients GLP-1 Medications for Weight Loss

Fras Juan, P

both are tools that may help individuals achieve their health goals, but neither can necessarily solve their respective health conditions for everyone (Srinivasan et al., 2025)

The orforglipron analysis looks at an oral GLP-1 agonist in development

Key Takeaways Retatrutide (LY3437943) is an investigational weight loss medication developed by Eli Lilly Triple-agonist mechanism: First drug to activate GLP-1, GIP, and glucagon receptors simultaneously Phase 2 results: Up to 24.2% weight loss at 48 weeks (approximately 58 lbs for a 240-lb person) Not FDA-approved: Currently in Phase 3 clinical trials, expected approval in 20272028 How it differs: Outperforms semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) in weight loss trials Access now: Clinical trials (free), compounding pharmacies, or research peptide vendors What Is Retatrutide

Heres the juicy part: eating healthy fats without a carb overload (hello, keto!) ramps up GLP-1 production even more

The corporate entities behind online clinics, compounding pharmacies, and other organizations involved in the dispensing chain could all face exposure